PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15269203-10	2004	In addition, it was shown that NBS1, SMC1, and p53 were phosphorylated in an ATM-dependent manner, and p53 phosphorylation on serine 20 is dependent on CHK2 after irofulven treatment.	irofulven	163-172	tumor protein p53	Homo sapiens	47-50	
15269203-10	2004	In addition, it was shown that NBS1, SMC1, and p53 were phosphorylated in an ATM-dependent manner, and p53 phosphorylation on serine 20 is dependent on CHK2 after irofulven treatment.	irofulven	163-172	tumor protein p53	Homo sapiens	103-106	
10368691-2	1999	In this study we examined cytotoxicity of MGI 114 against human tumor cell lines (MCF7, MDA.MB.468, EJ1, J82, SCaBER, KG-1, HL60, and IMR-90) with differing expression of p53 and/or p21 (WAF1) tumor suppressor genes.	irofulven	42-49	tumor protein p53	Homo sapiens	171-174	
12855662-3	2003	We have also evaluated the influence of major resistance mechanisms, such as expression of multidrug resistance-associated drug efflux pumps, cisplatin resistance, loss of p53 function, and absence of mismatch repair on the cytotoxic activity of irofulven.	irofulven	246-255	tumor protein p53	Homo sapiens	172-175	
17118344-0	2007	Irofulven induces replication-dependent CHK2 activation related to p53 status.	irofulven	0-9	tumor protein p53	Homo sapiens	67-70	
17118344-9	2007	Overall, this study demonstrates that in response to irofulven-induced DNA damage, the activation of CHK2 is dependent on DNA replication and related to p53 status.	irofulven	53-62	tumor protein p53	Homo sapiens	153-156	
17172419-6	2006	Previously, we have shown that irofulven activates ATM and its targets, NBS1, SMC1, CHK2, and p53.	irofulven	31-40	tumor protein p53	Homo sapiens	94-97